The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The city of Isanti is continuing to add to the recreational options of its primary park in the form of a sand volleyball ...

One stock to keep an eye on is Blue Bird (BLBD). BLBD is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. Investors will also notice that BLBD has a PEG ratio of 0.72. This metric ...

2seventy bio, the cell therapy spinout of Bluebird bio, is selling itself to Bristol Myers Squibb after losing most of its market value in its short run as an independent biotechnology company.

JPMorgan upgraded Bluebird Bio (BLUE) to Neutral from Underweight without a price target after the company entered into a definitive agreement to be taken private. The firm expects a completed ...

Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a publicly traded company. The agreement comes after years of financial ...

Flying high as one of the world’s premier developers of gene therapies in early 2018, bluebird bio’s share price hit a dizzying $2,300 apiece. But seven years later—after failing to build a ...

(RTTNews) - bluebird bio, Inc. (BLUE) announced Friday that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle Group, Inc. (CG ...

bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions ...

Blue Bird Corporation (BLBD) recently announced fiscal Q1 results, beating top and bottom-line expectations. While the company experienced a slight decline in net sales compared to the previous ...